(Total Views: 439)
Posted On: 08/22/2020 5:21:22 PM
Post# of 653
$RLFTF Reminder. 6pm est tonight. Coronavirus (COVID-19)
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
WhiteBoard style discussion on a pre-print case series (partially authored by the company that owns Aviptadil) on 21 patients with severe refractory COVID-19 all on ventilators and several on ECMO who failed multiple other therapies including remdesevir, tocilizumab, convalescent plasma, etc.
They were granted FDA emergency use authorization for intravenous Aviptadil (RLF-100). They saw significant improvements in the PaO2:FiO2 ratio, improvements in lung imaging, decreases in inflammatory markers, and improvements in the WHO ordinal scale. At 21 days, there was only a single death secondary to COVID-19 in this severely ill population.
Many had been discharged home on room air! Of note, this is a case series in pre-print partially authored by the company that owns Aviptadil, so there are many potential limitations!
https://youtu.be/QFAZjwxYZwo
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
WhiteBoard style discussion on a pre-print case series (partially authored by the company that owns Aviptadil) on 21 patients with severe refractory COVID-19 all on ventilators and several on ECMO who failed multiple other therapies including remdesevir, tocilizumab, convalescent plasma, etc.
They were granted FDA emergency use authorization for intravenous Aviptadil (RLF-100). They saw significant improvements in the PaO2:FiO2 ratio, improvements in lung imaging, decreases in inflammatory markers, and improvements in the WHO ordinal scale. At 21 days, there was only a single death secondary to COVID-19 in this severely ill population.
Many had been discharged home on room air! Of note, this is a case series in pre-print partially authored by the company that owns Aviptadil, so there are many potential limitations!
https://youtu.be/QFAZjwxYZwo
(0)
(0)
$MJ
